公开(公告)号：US07230156B2

公开(公告)日：2007-06-12

申请号：US11094286

申请日：2005-03-31

申请人： Wei Hu ,  Zuoyan Zhu ,  Yaping Wang ,  Shuangfei Li

发明人： Wei Hu ,  Zuoyan Zhu ,  Yaping Wang ,  Shuangfei Li

IPC分类号： A01K67/027 ,  C12N15/00

CPC分类号： C07K14/461 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/40 ,  A01K2267/02

摘要： The present application disclosed a method for preparing a sterile transgenic fish, comprising constructing antisense RNA expression vector of salmon-type gonadotropin-releasing hormone, introducing the recombinant DNA fragment into carp oosperm by microinjection, and screening the sterile transgenic fish by Polymerase Chain Reaction and radioimmunoassay, wherein the expression vector comprising a promoter of carp beta actin (β-actin) gene, a complementary DNA fragment of antisense salmon-type gonadotropin-releasing hormone (sGnRH) gene from carp with 323 bp as a target gene comprising sGnRH decapeptide, the coding region of gonadotropin-releasing hormone associated peptide and 3′ non-coding sequence, and 3′ flanking sequence of grass carp growth hormone gene as a stop sequence. The method of the present invention is easy and convenient for operation which provides a basis for providing a technical platform of general applicability for solving the hereditary and ecological safety problems of transgenic fishes.

摘要翻译： 本申请公开了一种制备无菌转基因鱼的方法，包括构建鲑鱼型促性腺激素释放激素的反义RNA表达载体，通过显微注射将重组DNA片段引入鲤鱼胚乳，并通过聚合酶链式反应筛选无菌转基因鱼， 放射免疫测定法，其中包含鲤鱼β肌动蛋白（β-肌动蛋白）基因启动子的表达载体，具有323bp作为靶基因的来自鲤鱼的反义鲑鱼型促性腺激素释放激素（sGnRH）基因的互补DNA片段，其包含sGnRH十肽， 促性腺激素释放激素相关肽和3'非编码序列的编码区和草鱼生长激素基因的3'侧翼序列作为停止序列。 本发明的方法操作简单方便，为提供解决转基因鱼遗传和生态安全问题的通用技术平台提供依据。

公开(公告)号：US20050070564A1

公开(公告)日：2005-03-31

申请号：US10489656

申请日：2002-09-13

申请人： Bohua Zhong ,  Zehui Gong ,  Yaping Wang ,  Yongshao Liu

发明人： Bohua Zhong ,  Zehui Gong ,  Yaping Wang ,  Yongshao Liu

IPC分类号： B42F1/00 ,  C07D489/12 ,  A61K31/485

CPC分类号： C07D489/12

摘要： The present invention relates to oripavine derivatives of formula (I), wherein R1 is hydrogen or methyl, R2 is methyl, cyclopropyl methyl, cyclobutyl methyl or allyl, R3 is thiophenyl ethyl or cycloalkyl methyl where the cycloalkyl has 3 to 6 carbon atoms, or nontoxic pharmaceutically acceptable salts thereof. These compounds can be used for the preparation of analgesics or abstinence agents of opium habit-forming drugs.

摘要翻译： 本发明涉及式（I）的oripavine衍生物，其中R 1是氢或甲基，R 2是甲基，环丙基甲基，环丁基甲基或烯丙基，R 3是噻吩基乙基或环烷基甲基，其中 环烷基具有3至6个碳原子，或其无毒的药学上可接受的盐。 这些化合物可用于制备鸦片习性形成药物的止痛剂或禁欲剂。

公开(公告)号：US20050004200A1

公开(公告)日：2005-01-06

申请号：US10741860

申请日：2003-12-19

申请人： Thomas Penning ,  Albert Khilevich ,  Barbara Chen ,  Preete Gandhi ,  Yaping Wang ,  Victoria Downs ,  Mark Boys ,  Mark Russell ,  Dale Spangler ,  Renee Huff

发明人： Thomas Penning ,  Albert Khilevich ,  Barbara Chen ,  Preete Gandhi ,  Yaping Wang ,  Victoria Downs ,  Mark Boys ,  Mark Russell ,  Dale Spangler ,  Renee Huff

IPC分类号： A61K31/415 ,  A61K31/416 ,  C07D401/14 ,  C07D405/14 ,  C07D471/04 ,  C07

CPC分类号： C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D471/04

摘要： The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αVβ3 and/or the αVβ5 integrin without significantly inhibiting the αVβ6 integrin.

摘要翻译： 本发明涉及一类由式I表示的化合物或其药学上可接受的盐，包含式I化合物的药物组合物以及选择性抑制或拮抗αVbeta3和/或αVβ5整联蛋白而不显着抑制αVβ6的方法 整合素

公开(公告)号：US20090156851A1

公开(公告)日：2009-06-18

申请号：US11990208

申请日：2006-08-10

申请人： Walter Weissensteiner ,  Yaping Wang ,  Felix Spindler ,  Benoit Pugin ,  Xiangdong Feng

发明人： Walter Weissensteiner ,  Yaping Wang ,  Felix Spindler ,  Benoit Pugin ,  Xiangdong Feng

IPC分类号： C07F9/02 ,  C07F15/02

CPC分类号： C07F17/02

摘要： Compounds of the formula (I) in the form of racemates, mixtures of stereoisomers or optically pure stereoisomers, formula (I), where X1 and X2 are each, independently of one another, a secondary phosphino group; R1 is a halogen atom or a—substituent bound via a C atom, N atom, S atom, Si atom, a P(O) group or a P(S) group to the cyclopentadienyl ring; R2 is C1-C4-alkyl or phenyl; m is from 1 to 3 and n is 0 or from 1 to 5, are ligands for complexes of transition metals as enantioselective and homogeneous catalysts. As a result of the substitution, the conversion, the stereoselectivity and/or the configuration of the adduct formed can be influenced and optimization of catalysts can be made possible in this way.

摘要翻译： 式（I）化合物为外消旋体形式，立体异构体混合物或光学纯立体异构体式（I），其中X1和X2各自独立地为次膦基; R1是通过C原子，N原子，S原子，Si原子，P（O）基团或P（S）键连接到环戊二烯基环上的卤素原子或取代基; R2是C1-C4烷基或苯基; m为1至3，n为0或1至5为过渡金属络合物作为对映选择性和均相催化剂的配体。 作为取代的结果，可以影响形成的加合物的转化率，立体选择性和/或构型，并且可以以这种方式使催化剂的优化成为可能。

公开(公告)号：US07119100B2

公开(公告)日：2006-10-10

申请号：US10489656

申请日：2002-09-13

申请人： Bohua Zhong ,  Zehui Gong ,  Yaping Wang ,  Yongshao Liu

发明人： Bohua Zhong ,  Zehui Gong ,  Yaping Wang ,  Yongshao Liu

IPC分类号： A61K31/44

CPC分类号： C07D489/12

摘要： The present invention relates to oripavine derivatives of formula (I), wherein R1 is hydrogen or methyl, R2 is methyl, cyclopropyl methyl, cyclobutyl methyl or allyl, R3 is thiophenyl ethyl or cycloalkyl methyl where the cycloalkyl has 3 to 6 carbon atoms, or non-toxic pharmaceutically acceptable salts thereof. These compounds can be used for the preparation of analgesics or abstinence agents of opium habit-forming drugs.

摘要翻译： 本发明涉及式（I）的oripavine衍生物，其中R 1是氢或甲基，R 2是甲基，环丙基甲基，环丁基甲基或烯丙基， 其中环烷基具有3至6个碳原子的噻吩基乙基或环烷基甲基，或其无毒的药学上可接受的盐。 这些化合物可用于制备鸦片习性形成药物的止痛剂或禁欲剂。

公开(公告)号：US20050004189A1

公开(公告)日：2005-01-06

申请号：US10741056

申请日：2003-12-19

申请人： John Wendt ,  Heather Stenmark ,  Hongwei Wu ,  Yaping Wang ,  Barbara Chen ,  Thomas Penning ,  Victoria Downs ,  Mark Boys ,  Mark Russell ,  Dale Spangler

发明人： John Wendt ,  Heather Stenmark ,  Hongwei Wu ,  Yaping Wang ,  Barbara Chen ,  Thomas Penning ,  Victoria Downs ,  Mark Boys ,  Mark Russell ,  Dale Spangler

IPC分类号： C07D417/14 ,  C07D471/04 ,  C07D417/02 ,  A61K31/426 ,  A61K31/427

CPC分类号： C07D417/14 ,  C07D471/04

摘要： The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or the αvβ5 integrin without significantly inhibiting the αvβ6 integrin.

摘要翻译： 本发明涉及一类由式I表示的化合物或其药学上可接受的盐，包含式I化合物的药物组合物，以及选择性抑制或拮抗阿尔法博乙和/或阿尔法肽5整联蛋白的方法，而不显着抑制alphavbeta6 整合素

公开(公告)号：US20090111994A1

公开(公告)日：2009-04-30

申请号：US11883972

申请日：2006-02-02

申请人： Yaping Wang ,  Yonggang Li ,  Yulin Li ,  Guojun Zheng ,  Yi Li

发明人： Yaping Wang ,  Yonggang Li ,  Yulin Li ,  Guojun Zheng ,  Yi Li

IPC分类号： C07D257/04

CPC分类号： C07C257/14 ,  C07D233/64 ,  C07D257/04 ,  C07D403/10 ,  Y02P20/55

摘要： The present invention relates to a novel process for preparing losartan, an imidazole derivative with the chemical name 2-n-butyl-4-chloro-5-hydroxymethyl-1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-]methyl}imidazole, and pharmacologically active salts thereof. The invention further relates to novel intermediates which are suitable for preparing losartan and to novel processes for preparing intermediate compounds which are suitable for preparing losartan.One aspect of the invention is a process for preparing a compound of the general formula I which can form as an intermediate in an inventive preparation of losartan.

摘要翻译： 本发明涉及一种制备氯沙坦的新方法，该化合物名为2-正丁基-4-氯-5-羟甲基-1 - {[2' - （1H-四唑-5-基）联苯 -4-]甲基}咪唑及其药理学活性盐。 本发明还涉及适用于制备氯沙坦的新型中间体和适用于制备氯沙坦的中间体化合物的新方法。 本发明的一个方面是制备可在本发明氯沙坦制剂中形成中间体的通式Ⅰ化合物的方法。

公开(公告)号：US20050257281A1

公开(公告)日：2005-11-17

申请号：US11094286

申请日：2005-03-31

申请人： Wei Hu ,  Zuoyan Zhu ,  Yaping Wang ,  Shuangfei Li

发明人： Wei Hu ,  Zuoyan Zhu ,  Yaping Wang ,  Shuangfei Li

IPC分类号： A01K61/00 ,  A01K67/027 ,  C07K14/46

CPC分类号： C07K14/461 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/40 ,  A01K2267/02

摘要： The present application disclosed a method for preparing a sterile transgenic fish, comprising constructing antisense RNA expression vector of salmon-type gonadotropin-releasing hormone, introducing the recombinant DNA fragment into carp oosperm by microinjection, and screening the sterile transgenic fish by Polymerase Chain Reaction and radioimmunoassay, wherein the expression vector comprising a promoter of carp beta actin (β-actin) gene, a complementary DNA fragment of antisense salmon-type gonadotropin-releasing hormone (sGnRH) gene from carp with 323 bp as a target gene comprising sGnRH decapeptide, the coding region of gonadotropin-releasing hormone associated peptide and 3′ non-coding sequence, and 3′ flanking sequence of grass carp growth hormone gene as a stop sequence. The method of the present invention is easy and convenient for operation which provides a basis for providing a technical platform of general applicability for solving the hereditary and ecological safety problems of transgenic fishes.

摘要翻译： 本申请公开了一种制备无菌转基因鱼的方法，包括构建鲑鱼型促性腺激素释放激素的反义RNA表达载体，通过显微注射将重组DNA片段引入鲤鱼胚乳，并通过聚合酶链式反应筛选无菌转基因鱼， 放射免疫测定法，其中包含鲤鱼β肌动蛋白（β-肌动蛋白）基因启动子的表达载体，具有323bp作为靶基因的来自鲤鱼的反义鲑鱼型促性腺激素释放激素（sGnRH）基因的互补DNA片段，其包含sGnRH十肽， 促性腺激素释放激素相关肽和3'非编码序列的编码区和草鱼生长激素基因的3'侧翼序列作为停止序列。 本发明的方法操作简单方便，为提供解决转基因鱼遗传和生态安全问题的通用技术平台提供依据。